Resources

Selected
  • Pneumococcal disease
Type of publications
Regions
Diseases
Methodological quality (AMSTAR 2)
266 results found
2024 ∙ NACI
Recommendations for public health programs on the use of pneumococcal vaccines in children, including the use of 15-valent and 20-valent conjugate vaccines
Recommendation Americas Canada Pneumococcal disease
Download:
2023 ∙ Eiden, Amanda L. Barratt, Jane Nyaku, Mawuli K.
A review of factors influencing vaccination policies and programs for older adults globally
Adults Older adults Influenza Pneumococcal disease Herpes zoster Tetanus Acceptance
Rating:
Not applicable
2023 ∙ Nagra, D. Bechman, K. Adas, M. Yang, Z. Alveyn, E. Subesinghe, S. Rutherford, A. Allen, V. Patel, S. Russell, M. D. Cope, A. Norton, S. Galloway, J.
A Systematic Review and Meta-Analysis of Anti-Rheumatic Drugs and Pneumococcal Vaccine Immunogenicity in Inflammatory Arthritis
All age groups Pneumococcal disease Efficacy/effectiveness
Rating:
Critically low
2023 ∙ Jagne, Isatou von Mollendorf, Claire Wee-Hee, Ashleigh Ortika, Belinda Satzke, Catherine Russell, Fiona M.
A systematic review of pneumococcal conjugate vaccine impact on pneumococcal nasopharyngeal colonisation density in children under 5 years of age
Newborn Children Pneumococcal disease Efficacy/effectiveness
Rating:
Low
2023 ∙ Doggen, Kris van Hoek, Albert Jan Luyten, Jeroen
Accounting for Adverse Events Following Immunization in Economic Evaluation: Systematic Review of Economic Evaluations of Pediatric Vaccines Against Pneumococcus, Rotavirus, Human Papillomavirus, Meningococcus and Measles-Mumps-Rubella-Varicella
Newborn Children Adolescents Adults Pneumococcal disease Rotavirus Human papillomavirus (HPV) Meningococcal disease Mumps Measles Rubella Economic aspects
Rating:
Not applicable
2023 ∙ Pichichero, Michael Malley, Richard Kaur, Ravinder Zagursky, Robert Anderson, Porter
Acute otitis media pneumococcal disease burden and nasopharyngeal colonization in children due to serotypes included and not included in current and new pneumococcal conjugate vaccines
Children Adolescents Pneumococcal disease Efficacy/effectiveness Efficacy/effectiveness
Rating:
Critically low
2023 ∙ Scheffer, M. M. J. Coffeng, L. E. O'Mahony, J. F.
Appropriateness of strategy comparisons in cost-effectiveness analyses of infant pneumococcal vaccination: A systematic review
Newborn Pneumococcal disease Economic aspects
Rating:
Not applicable
2023 ∙ Du, Yuanze Wang, Yi Zhang, Ting Li, Juanjuan Song, Hewei Wang, Yuanyuan Xu, Yifei Cui, Jingwen Yang, Ming Wang, Zengwu Wu, Xiuyun Wang, Chunping
Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review
All age groups Pneumococcal disease Economic aspects
Rating:
Not applicable
2023 ∙ Del Riccio, M. Boccalini, S. Cosma, C. Vaccaro, G. Bonito, B. Zanella, B. Salvati, C. Giorgetti, D. Rigon, L. Biamonte, M. A. Monami, M. Bonanni, P. Bechini, A.
Effectiveness of pneumococcal vaccination on hospitalization and death in the adult and older adult diabetic population: a systematic review
Adults Older adults Pneumococcal disease Efficacy/effectiveness
Rating:
Low
2023 ∙ Wannarong, T. Ekpatanaparnich, P. Boonyasiri, A. Supapueng, O. Vathanophas, V. Tanphaichitr, A. Ungkanont, K.
Efficacy of Pneumococcal Vaccine on Otitis Media: A Systematic Review and Meta-Analysis
Newborn Children Pneumococcal disease Efficacy/effectiveness
Rating:
Low
Loading...